Skip to main content
Clinical Trials/EUCTR2009-013355-29-GB
EUCTR2009-013355-29-GB
Active, not recruiting
Phase 1

A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered synacthen and salivary cortisol. The validated non-invasive SST will be used to establish normative data in children and to detect adrenal suppression in asthmatic children. - The development of a non-invasive Short Synacthen Test - NeSST Study

Sheffield Children's NHS Foundation Hospital0 sites258 target enrollmentJune 24, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establish normal ranges for the adrenal response to a low-dose synacthen test. In stage 4 adrenal function in asthmatic individuals on inhaled corticosteroids will be studied.
Sponsor
Sheffield Children's NHS Foundation Hospital
Enrollment
258
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 24, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Sheffield Children's NHS Foundation Hospital

Eligibility Criteria

Inclusion Criteria

  • Stage 1(a\+b): Healthy, male volunteers aged 18\-64, with no exclusion criteria listed below.
  • Stage 2: Healthy children of either sex, aged between 2 years and 15 years, with no exclusion criteria listed below.
  • Stage 3: Healthy children of both sexes, aged between 6 months and 15 years, without exclusion criteria 1,2,3,5,6,7,8,9,10,11,12 and 14 listed below.
  • Phase 4: Children of both sexes, aged between 6 months and 15 years, prescribed varying doses of regular inhaled corticosteroids and without exclusion criteria 1,5,9,10,11,12 and 14 as listed below.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\. Past or present history of an endocrinopathy.
  • 2\. Past or present history of asthma.
  • 3\. Past or present history of allergic rhinitis
  • 4\. Past or present history of peptic ulcer disease/GI bleed/significant dyspepsia.
  • 5\. Past history of intra\-cranial, renal or adrenal pathology.
  • 6\. Presently on any prescribed medication.
  • 7\. Presently, or within the last 3 months, been prescribed any type of corticosteroid (oral, inhaled, nasal, rectal, intravenous, intramuscular, intra\-articular, intra\-ocular, topical).
  • 8\. Ever been prescribed a prolonged course (more than 1 month) of oral steroids.
  • 9\. Previous serious allergic reaction or an episode of anaphylaxis.
  • 10\. Previous adverse reaction (including mild hypersensitivity)to ACTH or synacthen.

Outcomes

Primary Outcomes

Not specified

Similar Trials